ST未名: 《公司章程》（2025年7月）

Core Points - The company is Shandong Sinobioway Biomedicine Co., Ltd., established in accordance with Chinese laws and regulations, with a registered capital of RMB 659,735,586 [2][6] - The company focuses on the biomedicine sector, aiming to address health issues through pharmaceutical research, manufacturing, and related services [4][5] - The company was approved for its initial public offering (IPO) in 2011, issuing 27.08 million shares [3] Company Structure - The company is a permanent corporation, with its legal representative being the board director or general manager [2][8] - The company has a total of 659,735,586 shares, all of which are ordinary shares [7][21] - The company is governed by its articles of association, which are legally binding for the company, shareholders, and management [3][12] Business Operations - The company's business scope includes biotechnology research, production and sales of pharmaceuticals, medical devices, and health management services [5][14] - The company aims to enhance its competitive edge in both domestic and international markets by integrating resources and improving innovation capabilities [4][14] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company decisions, as well as obligations to comply with laws and the company's articles of association [13][40] - The company has provisions for shareholder meetings, including the requirement for a quorum and voting procedures [20][79] Governance and Compliance - The company is required to maintain transparency and comply with regulations regarding shareholder rights, including the disclosure of significant events [18][19] - The articles of association outline the responsibilities of controlling shareholders and actual controllers to protect the interests of the company and other shareholders [41][42]